This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Identity of ImClone Suitor Will Have to Wait

Updated from Wednesday, Oct. 1

Investors will wait longer yet for affirmation or more information about the mystery bidder for ImClone Systems (IMCL), according to a statement late Wednesday.

ImClone Chairman Carl Icahn said in a release that the mystery bidder for ImClone has made a proposal not subject to financing or further due diligence. Negotiations are reportedly underway and the company has requested that ImClone not reveal the bidder's name until negotiations are complete.

The Wall Street Journal reported earlier Wednesday evening that Eli Lilly (LLY - Get Report) was the mystery bidder "in advanced talks" to buy ImClone for $70 a share.

The deal, yet to be confirmed by either company, would value ImClone at $6.1 billion.

By acquiring ImClone, Lilly would gain a marketed cancer drug, Erbitux, but just as important -- perhaps even more important to Lilly -- is gaining control over ImClone's know-how in developing and manufacturing biologic (i.e. biotech) drugs.

A further plus for Lilly is ImClone's pipeline of five cancer drugs in various stages of early and mid-stage clinical trials. This would beef up Lilly's internal cancer drug pipeline.

Alimta, Lilly's biggest cancer drug that is approved for the treatment of non-small cell lung cancer, reported sales of $522 million in the first six months of 2008, a 32% increase over the first six months of 2007.

Alimta and Erbitux may not necessarily compete in lung cancer because Alimta cannot be used to treat patients with so-called squamous form of non-small cell lung cancer. Squamous cell is one of the most common forms of non-small cell lung cancer. Erbitux, however, is likely to be used in patients with squamous non-small cell lung cancer, based on the phase III clinical data presented earlier this year.

The pre-announced due diligence period for the mystery bidder expired on Sunday, and ImClone said on Monday that the potential suitor would make up its mind by Wednesday. The company would either make a firm offer or withdraw by that deadline, and its name would be divulged if it withdrew its proposal.

Bristol-Myers Squibb (BMY) last week announced its intent to go hostile with its own bid for the company, raising it to $62 a share and going directly to shareholders.

ImClone's Icahn dismissed the hostile tender offer as "misleading" and "absurd."

ImClone is best known for its Erbitux cancer drug, which Bristol-Myers sells in the U.S. German company Merck KGaA sells the drug in Europe.

ImClone shares were up $2.69, or 4.3%, at $65.09 in after-hours trading, while Lilly's shares edged down 31 cents, or 0.7%, at $43.72. Rival bidder Bristol-Myers shares were up 25 cents, or 1.2%, at $20.79 in the post-market.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
IMCL $5.40 -3.57%
BMY $61.46 0.39%
LLY $70.03 -0.47%
AAPL $130.42 1.26%
FB $80.41 1.07%

Markets

DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs